Plant-Derived Bioactive Compounds as Potential Therapeutics in Neurodegenerative Diseases: A Pharmacological Insight
Main Article Content
Abstract
Plant-derived bioactive compounds have provided an attractive and versatile approach to address the challenge of neurodegenerative diseases that remain a critical global health concern due to progressive progression and lack of therapeutic treatment. These diseases include Alzheimer, Parkinson, and Huntington and are characterized by complex pathologies and include oxidative stress, abnormal protein aggregation, mitochondrial dysfunction, neuroinflammation, and neuronal apoptosis that eventually lead to impaired cognition, mobility, and general neurobiological functioning. The traditional pharmacological treatment methods mainly offer relief in the form of symptoms and have a minimal effect of slowing down the process of disease, which is why new forms of treatment are urgently needed. The recent pharmacological studies have progressively emphasized the strong medicinal potential of plant bioactive components, including polyphenols, alkaloids, flavonoids, terpenoids, and polysaccharides. These constituents show a biomolecular range of neuroprotective effects such as antioxidant, anti-inflammatory, anti-apoptotic, anti-cholinesterase as well as anti-aggregation which are direct antagonists of the pathological processes of neurodegeneration.
Consistently, both preclinical in vitro and in vivo experiments reveal that these secondary metabolites are capable of alleviating neuronal damage through the effect of modulating cellular signalling pathways, reactive oxygen species, supporting mitochondrial activity, and inhibition of apoptotic cascades. Bacosides (derived with Bacopa monnieri), acteoside, and pinocembrin have been found to, respectively, inhibit neuronal apoptosis, confer anti-inflammatory and antioxidant properties critical to neuroprotection. The growing body of evidence that functional synergy exists between plant-derived compounds and current pharmacotherapies indicates that combination strategies could be used to improve therapeutic outcomes and elevate clinical outcomes.
Article Details
Section
How to Cite
References
1. Chaachouay, N., & Zidane, L. (2024). Plant-derived natural products: a source for drug discovery and development. Drugs and Drug Candidates, 3(1), 184-207.
2. Shoaib, S., Ansari, M. A., Fatease, A. A., Safhi, A. Y., Hani, U., Jahan, R., ... & Islam, N. (2023). Plant-derived bioactive compounds in the management of neurodegenerative disorders: challenges, future directions and molecular mechanisms involved in neuroprotection. Pharmaceutics, 15(3), 749.
3. Nunes, Y. C., Mendes, N. M., Pereira de Lima, E., Chehadi, A. C., Lamas, C. B., Haber, J. F., ... & Marin, M. J. S. (2024). Curcumin: A golden approach to healthy aging: A systematic review of the evidence. Nutrients, 16(16), 2721.
4. Islam, M. R., Al‐Imran, M. I. K., Zehravi, M., Sweilam, S. H., Mortuza, M. R., Gupta, J. K., ... & Emran, T. B. (2025). Targeting signaling pathways in neurodegenerative diseases: Quercetin's cellular and molecular mechanisms for neuroprotection. Animal Models and Experimental Medicine, 8(5), 798-818.
5. Kaspute, G., Ramanavicius, A., & Prentice, U. (2025). Natural drug delivery systems for the treatment of neurodegenerative diseases. Molecular Biology Reports, 52(1), 217.
6. Rahman, M. H., Bajgai, J., Fadriquela, A., Sharma, S., Trinh, T. T., Akter, R., ... & Lee, K. J. (2021). Therapeutic potential of natural products in treating neurodegenerative disorders and their future prospects and challenges. Molecules, 26(17), 5327.
7. Iqubal, A., Rahman, S. O., Ahmed, M., Bansal, P., Haider, M. R., Iqubal, M. K., ... & Haque, S. E. (2021). current quest in natural bioactive compounds for Alzheimer’s disease: Multi-targeted-designed-ligand based approach with preclinical and clinical based evidence. Current Drug Targets, 22(6), 685-720.
8. Cario, A., & Berger, C. L. (2023). Tau, microtubule dynamics, and axonal transport: New paradigms for neurodegenerative disease. Bioessays, 45(8), 2200138.
9. Buccellato, F. R., D’Anca, M., Fenoglio, C., Scarpini, E., & Galimberti, D. (2021). Role of oxidative damage in Alzheimer’s disease and neurodegeneration: From pathogenic mechanisms to biomarker discovery. Antioxidants, 10(9), 1353.
10. Ayoub, S., Arabi, M., Al-Najjar, Y., Laswi, I., Outeiro, T. F., & Chaari, A. (2025). Glycation in Alzheimer’s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions. Molecular Neurobiology, 1-24.
11. Nicosia, N., Giovenzana, M., Misztak, P., Mingardi, J., & Musazzi, L. (2024). Glutamate-mediated excitotoxicity in the pathogenesis and treatment of neurodevelopmental and adult mental disorders. International Journal of Molecular Sciences, 25(12), 6521.
12. Fatima, R., Khan, Y., Maqbool, M., Ramalingam, P. S., Khan, M. G., Bisht, A. S., & Hussain, M. S. (2025). Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer’s Treatment. Current protein & peptide science.
13. Latif, S., Jahangeer, M., Razia, D. M., Ashiq, M., Ghaffar, A., Akram, M., ... & Ansari, M. A. (2021). Dopamine in Parkinson's disease. Clinica chimica acta, 522, 114-126.
14. Jurcău, M. C., Andronie-Cioara, F. L., Jurcău, A., Marcu, F., Ţiț, D. M., Pașcalău, N., & Nistor-Cseppentö, D. C. (2022). The link between oxidative stress, mitochondrial dysfunction and neuroinflammation in the pathophysiology of Alzheimer’s disease: therapeutic implications and future perspectives. Antioxidants, 11(11), 2167.
15. Lee, J. H. (2023). Understanding Parkinson's Disorders: Classification and Evaluation Methods, Movement Disorders, and Treatment Methods. International Journal of Advanced Culture Technology (IJACT), 11(3), 9-17.
16. Wu, W. L., Gong, X. X., Qin, Z. H., & Wang, Y. (2025). Molecular mechanisms of excitotoxicity and their relevance to the pathogenesis of neurodegenerative diseases—an update. Acta Pharmacologica Sinica, 1-14.
17. Saini, N., Singh, N., Kaur, N., Garg, S., Kaur, M., Kumar, A., ... & Sohal, H. S. (2024). Motor and non-motor symptoms, drugs, and their mode of action in Parkinson’s disease (PD): a review. Medicinal Chemistry Research, 33(4), 580-599.
18. Donaldson, J., Powell, S., Rickards, N., Holmans, P., & Jones, L. (2021). What is the pathogenic CAG expansion length in Huntington’s disease?. Journal of Huntington's Disease, 10(1), 175-202.
19. Alharbi, B., Al-Kuraishy, H. M., Al-Gareeb, A. I., Elekhnawy, E., Alharbi, H., Alexiou, A., ... & Batiha, G. E. S. (2024). Role of GABA pathway in motor and non-motor symptoms in Parkinson's disease: a bidirectional circuit. European Journal of Medical Research, 29(1), 205.
20. Iskusnykh, I. Y., Zakharova, A. A., Kryl’skii, E. D., & Popova, T. N. (2024). Aging, neurodegenerative disorders, and cerebellum. International Journal of Molecular Sciences, 25(2), 1018.
21. Brogueira Rodrigues, F. (2024). Enhancing clinical trials methodology in Huntington’s disease (Doctoral dissertation, UCL (University College London)).
22. Asuku, A. O., Ajagun, E. J., & Ogungbangbe, G. O. (Eds.). (2025). Non-Pharmacological Interventions for Dementia: A Comprehensive Approach. CRC Press.
23. , Gohil, N. D. (2024). PHARMACOLOGICAL TREATMENTS AND THERAPEUTIC APPROACHES FOR HUNTINGTON'S DISEASE
24. Pinto, T., Aires, A., Cosme, F., Bacelar, E., Morais, M. C., Oliveira, I., ... & Gonçalves, B. (2021). Bioactive (poly) phenols, volatile compounds from vegetables, medicinal and aromatic plants. Foods, 10(1), 106.
25. Rodriguez, R., Müller, S., Colombeau, L., Solier, S., Sindikubwabo, F., & Cañeque, T. (2025). Metal ion signaling in biomedicine. Chemical reviews, 125(2), 660-744.
26. Liu, J., Guan, Y., Yang, L., Fang, H., Sun, H., Sun, Y., ... & Wang, X. (2025). Ferulic Acid as an Anti-Inflammatory Agent: Insights into Molecular Mechanisms, Pharmacokinetics and Applications. Pharmaceuticals, 18(6), 912.
27. Verma, M. K., Singh, B. K., & Tripathi, M. (2024). Benefits of Phytoestrogens. Herbs and Spices-New Perspectives in Human Health and Food Industry: New Perspectives in Human Health and Food Industry, 109.
28. Mishra, Y., & Mishra, V. (2024). Treatment of Breast Cancer with Natural Products. Elsevier.
29. Bertoncini-Silva, C., Vlad, A., Ricciarelli, R., Giacomo Fassini, P., Suen, V. M. M., & Zingg, J. M. (2024). Enhancing the bioavailability and bioactivity of curcumin for disease prevention and treatment. Antioxidants, 13(3), 331.
30. AlHayani, D. A., Kubaev, A., Uthirapathy, S., Mandaliya, V., Ballal, S., Kalia, R., ... & Kadhim, A. J. (2025). Insights Into the Therapeutic Potential of SIRT1-modifying Compounds for Alzheimer’s Disease: A Focus on Molecular Mechanisms. Journal of Molecular Neuroscience, 75(1),29.
31. Avgerinos, K. I., Ferrucci, L., & Kapogiannis, D. (2021). Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease. Ageing research reviews, 68, 101339.
32. Rodríguez-Arce, E., & Saldías, M. (2021). Antioxidant properties of flavonoid metal complexes and their potential inclusion in the development of novel strategies for the treatment against neurodegenerative diseases. Biomedicine & Pharmacotherapy, 143, 112236.
33. Al Amin, M., Dehbia, Z., Nafady, M. H., Zehravi, M., Kumar, K. P., Haque, M. A., ... & Emran, T. B. (2025). Flavonoids and Alzheimer’s disease: reviewing the evidence for neuroprotective potential. Molecular and Cellular Biochemistry, 480(1), 43-73.
34. Firdous, S. M., Pal, S., Mandal, S., & Sindhu, R. K. (2025). Antioxidants in Inflammatory Diseases. Antioxidants: Nature's Defense Against Disease, 83-126.
35. Zhang, S., & Kiarasi, F. (2024). Therapeutic effects of resveratrol on epigenetic mechanisms in age‐related diseases: A comprehensive review. Phytotherapy Research, 38(5), 2347-2360.
36. Shruti, V., Rani, K. S., & Patani, P. (2024). A Review On Emerging Potential Benefits Of Pumpkin Seed, Flax Seed, Sunflower Seed, Sesame Seed And Cinnamon In Management Of Hormonal Imbalance. Eurasian Journal of Analytical Chemistry, 19(1).
37. Obulesu, M. (2021). Turmeric and curcumin for neurodegenerative diseases. Academic Press.
38. Hasan, S., Khatri, N., Rahman, Z. N., Menezes, A. A., Martini, J., Shehjar, F., ... & Shah, Z. A. (2023). Neuroprotective potential of flavonoids in brain disorders. Brain sciences, 13(9), 1258.
39. Singh, D. K., Kumar, B., Sinha, S., & Fatima, K. (2024). Phytochemicals for the Improvement of Cognitive Function through Cholinergic Anti-inflammatory Pathway. Current Indian Science, e2210299X309791.
40. Chatterjee, A. (2026). Plant-Based Remedies for Alzheimer's Disease. In Herbal Medicines and Nutritional Supplements for Health Benefits (pp. 449-476). Apple Academic Press.
41. Tian, E., Sharma, G., & Dai, C. (2023). Neuroprotective properties of berberine: molecular mechanisms and clinical implications. Antioxidants, 12(10), 1883.
42. . Câmara, J. S., Perestrelo, R., Ferreira, R., Berenguer, C. V., Pereira, J. A., & Castilho, P. C. (2024). Plant-derived terpenoids: A plethora of bioactive compounds with several health functions and industrial applications—A comprehensive overview. Molecules, 29(16), 3861.
43. de Lima, E. P., Laurindo, L. F., Catharin, V. C. S., Direito, R., Tanaka, M., Jasmin Santos German, I., ... & Barbalho, S. M. (2025). Polyphenols, alkaloids, and terpenoids against neurodegeneration: Evaluating the neuroprotective effects of phytocompounds through a comprehensive review of the current evidence. Metabolites, 15(2), 124.
44. Nowak, A., Kojder, K., Zielonka-Brzezicka, J., Wróbel, J., Bosiacki, M., Fabiańska, M., ... & Klimowicz, A. (2021). The use of Ginkgo biloba L. as a neuroprotective agent in the Alzheimer’s disease. Frontiers in pharmacology, 12, 775034.
45. Naureen, Z., Dhuli, K., Medori, M. C., Caruso, P., Manganotti, P., Chiurazzi, P., & Bertelli, M. (2022). Dietary supplements in neurological diseases and brain aging. Journal of preventive medicine and hygiene, 63(2 Suppl 3), E174.
46. . Babayeva, M., & Loewy, Z. G. (2024). Cannabis Compounds: Potential Therapy for Neurological Disease. Medicinal Plants-Harnessing the Healing Power of Plants: Harnessing the Healing Power of Plants, 3.
47. Prasad, D. R., Maurya, B., & Mishra, A. (2022). Neuroprotective Effect of Ginkgo Biloba and its Role in Alzheimer’s Disease. In Indopathy for Neuroprotection: Recent Advances (pp. 258-280). Bentham Science Publishers.
48. Mursal, M., Kumar, A., Hasan, S. M., Hussain, S., Singh, K., Kushwaha, S. P., ... & Fatima, S. K. (2024). Role of natural bioactive compounds in the management of neurodegenerative disorders. Intelligent Pharmacy, 2(1), 102-113.
49. . Wilbourn, N. (2025). The Implications of the Scientific Developments Behind Oxidative Stress, Heat-Shock Proteins, and Antioxidants on Neurodegenerative Pathology.
50. . Hassan, H. A., Ahmed, H. S., & Hassan, D. F. (2024). Free radicals and oxidative stress: Mechanisms and therapeutic targets. Human Antibodies, 32(4), 151-167.
51. Andrés, C. M. C., Pérez de la Lastra, J. M., Bustamante Munguira, E., Juan, C. A., Plou, F. J., & Pérez Lebeña, E. (2024). Electrophilic compounds in the human diet and their role in the induction of the transcription factor NRF2. International Journal of Molecular Sciences, 25(6), 3521.
52. . Zhang, Y., Zhang, W., Zhao, Y., Peng, R., Zhang, Z., Xu, Z., ... & Deng, J. (2025). Bioactive sulforaphane from cruciferous vegetables: advances in biosynthesis, metabolism, bioavailability, delivery, health benefits, and applications. Critical Reviews in Food Science and Nutrition, 65(15), 3027-3047.
53. Dhurandhar, Y., Tomar, S., Das, A., Prajapati, J. L., Singh, A. P., Bodake, S. H., & Namdeo, K. P. (2025). Chronic inflammation in obesity and neurodegenerative diseases: exploring the link in disease onset and progression. Molecular Biology Reports, 52(1), 1-20.
54. Kaur, K., Al-Khazaleh, A. K., Bhuyan, D. J., Li, F., & Li, C. G. (2024). A review of recent curcumin analogues and their antioxidant, anti-inflammatory, and anticancer activities. Antioxidants, 13(9), 1092.
55. Avola, R., Furnari, A. G., Graziano, A. C. E., Russo, A., & Cardile, V. (2024). Management of the brain: Essential oils as promising neuroinflammation modulator in neurodegenerative diseases. Antioxidants, 13(2), 178.
56. Tahmasebi, F., Asl, E. R., Faghihi, F., Bolandi, N., & Barati, S. (2025). Synergistic Effects of Olfactory Ecto-Mesenchymal Stem Cell Supernatant and Ellagic Acid on Demyelination and Glial Modulation in a Chronic Multiple Sclerosis Model. Cellular and Molecular Neurobiology, 45(1), 1-14.
57. Seychell, R. M., El Saghir, A., & Vassallo, N. (2024). Modulation of Biological Membranes Using Small-Molecule Compounds to Counter Toxicity Caused by Amyloidogenic Proteins. Membranes, 14(11), 231.
58. Lehoczki, A., Fekete, M., Jarecsny, T., Zábó, V., Szappanos, Á., Csípő, T., ... & Varga, J. T. (2025). The Neuroprotective Role of Curcumin: From Molecular Pathways to Clinical Translation—A Narrative Review. Nutrients, 17(17), 2884.
59. Perluigi, M., Di Domenico, F., & Butterfield, D. A. (2024). Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease. Physiological Reviews, 104(1), 103-197.
60. Wang, F., Huynh, P. M., & An, Y. A. (2024). Mitochondrial function and dysfunction in white adipocytes and therapeutic implications. Comprehensive Physiology, 14(4), 5581-5640.
61. Chen, D., Duan, Y., Yu, S., Zhang, X., Li, N., & Li, J. (2022). Rutaecarpine promotes adipose thermogenesis and protects against HFD-induced obesity via AMPK/PGC-1α pathway. Pharmaceuticals, 15(4), 469.
62. Koklesova, L., Liskova, A., Samec, M., Zhai, K., Al-Ishaq, R. K., Bugos, O., ... & Golubnitschaja, O. (2021). Protective effects of flavonoids against mitochondriopathies and associated pathologies: focus on the predictive approach and personalized prevention. International journal of molecular sciences, 22(16), 8649.
63. Elbakary, B. (2021). The role of phytochemicals in modulating breast cancer resistance protein at the blood-brain barrier and the blood-tumour barrier (Doctoral dissertation, Aston University).
64. Yang, X., Hu, D., Cheng, R., Bao, Q., Jiang, H., Zhao, B., & Zhang, Y. (2025). Unlocking the neuroprotective secrets of natural products: a focus on the gut-brain axis. Phytochemistry Reviews, 1-44.
65. . Hoang, L. N., Lee, H., & Lee, S. J. (2025). Improving cognitive impairment through chronic consumption of natural compounds/extracts: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Aging Neuroscience, 16, 1531278.
66. Clemente-Suárez, V. J., Martín-Rodríguez, A., Curiel-Regueros, A., Rubio-Zarapuz, A., & Tornero-Aguilera, J. F. (2025). Neuro-nutrition and exercise synergy: exploring the bioengineering of cognitive enhancement and mental health optimization. Bioengineering, 12(2), 208.
67. Grabska-Kobyłecka, I., Szpakowski, P., Król, A., Książek-Winiarek, D., Kobyłecki, A., Głąbiński, A., & Nowak, D. (2023). Polyphenols and their impact on the prevention of neurodegenerative diseases and development. Nutrients, 15(15), 3454.
68. Hirani, K., Sundheim, B., Blaschke, M., Lemos, J. R., & Mittal, R. (2025). A global call to action: strengthening strategies to combat dysglycemia and improve public health outcomes. Frontiers in Public Health, 13, 1597128.
69. Grabarczyk, M., Justyńska, W., Czpakowska, J., Smolińska, E., Bielenin, A., Glabinski, A., & Szpakowski, P. (2024). Role of plant phytochemicals: Resveratrol, curcumin, luteolin and quercetin in demyelination, neurodegeneration, and epilepsy. Antioxidants, 13(11), 1364.
70. Piantadosi, S. (2024). Clinical trials: a methodologic perspective. John Wiley & Sons.
71. . Alum, E. U., Manjula, V. S., Uti, D. E., Echegu, D. A., Ugwu, O. P. C., Egba, S. I., & Agu, P. C. (2025). Metabolomics-driven standardization of herbal medicine: advances, applications, and sustainability considerations. Natural Product Communications, 20(8), 1934578X251367650.
72. Wang, H., Chen, Y., Wang, L., Liu, Q., Yang, S., & Wang, C. (2023). Advancing herbal medicine: enhancing product quality and safety through robust quality control practices. Frontiers in pharmacology, 14, 1265178.
73. Alzola, P., Carnero, C., Bermejo-Pareja, F., Sanchez-Benavides, G., Pena-Casanova, J., Puertas-Martin, V., ... & Contador, I. (2024). Neuropsychological assessment for early detection and diagnosis of dementia: current knowledge and new insights. Journal of Clinical Medicine, 13(12), 3442.
74. Alqahtani, M. M. A., Asiri, M. M., Alqahtani, S. S. S., Asiri, M. A. M., Alasmari, F. A. M., & Mashni, A. M. A. (2024). Advancements in Biomarker Testing for Cancer Patients: A Comprehensive Review. Journal of International Crisis and Risk Communication Research, 7(S9), 1285.
75. Singh, S., Chib, S., Akhtar, M. J., Kumar, B., Chawla, P. A., & Bhatia, R. (2024). Paradigms and success stories of natural products in drug discovery against neurodegenerative disorders (NDDs). Current Neuropharmacology, 22(6), 992-1015.
76. . Goyal, R., Mittal, P., Gautam, R. K., Kamal, M. A., Perveen, A., Garg, V., ... & Ashraf, G. M. (2024). Natural products in the management of neurodegenerative diseases. Nutrition & metabolism, 21(1), 26.
77. Hossain, M. S., & Hussain, M. H. (2025). Multi‐Target Drug Design in Alzheimer's Disease Treatment: Emerging Technologies, Advantages, Challenges, and Limitations. Pharmacology Research & Perspectives, 13(4), e70131.
78. . Ilic, K. (2025). Biomarkers as surrogate endpoints in drug development: finding their right place. Clinical Therapeutics.
79. Sharma, R., Gulati, A., & Chopra, K. (2025). Era of surrogate endpoints and accelerated approvals: a comprehensive review on applicability, uncertainties, and challenges from regulatory, payer, and patient perspectives. European Journal of Clinical Pharmacology, 1-19.
80. Nahar, L., Charoensup, R., Kalieva, K., Habibi, E., Guo, M., Wang, D., ... & Sarker, S. D. (2025). Natural products in neurodegenerative diseases: recent advances and future outlook. Frontiers in Pharmacology, 16, 1529194.
81. Busia, K. (2024). Herbal medicine dosage standardisation. Journal of Herbal Medicine, 46, 100889.
82. . Gupta, D. K., Tiwari, A., Yadav, Y., Soni, P., & Joshi, M. (2024). Ensuring safety and efficacy in combination products: regulatory challenges and best practices. Frontiers in Medical Technology, 6, 1377443.
83. Su, H., Fuentes, A. L., Chen, H., Malhotra, A., Gallo, L. C., Song, Y., ... & Kamdar, B. B. (2024). The Financial Impact of Post Intensive Care Syndrome. Critical care clinics, 41(1), 103.
84. Mahboob, A., Ali, H., Alnaimi, A., Yousef, M., Rob, M., Al-Muhannadi, N. A., ... & Chaari, A. (2024). Immunotherapy for Parkinson’s disease and Alzheimer’s disease: A promising disease-modifying therapy. Cells, 13(18), 1527.
85. Simoens, S. (2022). Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies. Frontiers in neurology, 13, 1015256.
86. Aktary, N., Jeong, Y., Oh, S., Shin, Y., Sung, Y., Rahman, M., ... & Kim, B. (2025). Unveiling the therapeutic potential of natural products in Alzheimer’s disease: insights from in vitro, in vivo, and clinical studies. Frontiers in Pharmacology, 16, 1601712.